Success Metrics

Clinical Success Rate
14.3%

Based on 1 completed trials

Completion Rate
14%(1/7)
Active Trials
0(0%)
Results Posted
700%(7 trials)
Terminated
6(86%)

Phase Distribution

Ph phase_1
1
14%
Ph phase_3
6
86%

Phase Distribution

1

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 3Large-scale testing
6(85.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

14.3%

1 of 7 finished

Non-Completion Rate

85.7%

6 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(1)
Terminated(6)

Detailed Status

Terminated6
Completed1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
14.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 36 (85.7%)

Trials by Status

terminated686%
completed114%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_1

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT07052682
terminatedphase_3

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

NCT03627091
completedphase_3

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03290781
terminatedphase_3

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259334
terminatedphase_3

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

NCT03566823
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07052682Phase 1

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

Terminated
NCT03627091Phase 3

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

Terminated
NCT03290781Phase 3

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

Completed
NCT03259334Phase 3

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Terminated
NCT03566823Phase 3

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

Terminated
NCT03559517Phase 3

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

Terminated
NCT03259308Phase 3

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7